1) WAY-100635,6-hydroxydopamine
WAY-100635,6-羟多巴胺
3) 6-hydroxydopamine
6-羟多巴胺
1.
Objective To study the protective effects and mechanism of melatonin(MT) precondition on Parkinson disease(PD) brain slice of substantia nigra(SN,in vitro) induced by 6-hydroxydopamine(6-OHDA).
目的研究褪黑素(melatonin,MT)对6-羟多巴胺(6-hydroxydopamine,6-OHDA)所制造的离体帕金森病(Pakinson disease,PD)模型的影响。
2.
METHODS:SD rat model of Parkinson s disease was established by lesion induction in substantia nigra compacta(SNc)by 6-hydroxydopamine.
方法:以6-羟多巴胺(6-OHDA)毁损黑质致密部(SNc)建立的PD模型大鼠为研究对象,采用玻璃微电极细胞外记录方法,记录和分析了PD状态下腹内侧前额叶皮层中神经元的电活动变化。
3.
?Methods 6-hydroxydopamine(6-OHDA) was injected into the rats unilateral striatum.
方法成年大鼠单侧纹状体内注射6-羟多巴胺(6-hydroxydopamine,6-OHDA)。
4) 6-OHDA
6-羟多巴胺
1.
Effects of 6-OHDA on the body weight and structure of small intestinal mucosa in mice;
6-羟多巴胺对小鼠体重及其小肠黏膜结构的影响
2.
Objective To observe the morphologic changes of dopaminergic neurons in the substantia nigra of!Parkinson s disease (PD) rats that received a unilateral injection of 6-hydroxydopamine(6-OHDA).
目的观察6-羟多巴胺(6-OHDA)单侧注射制备的帕金森病(PD)大鼠多巴胺(DA)能神经元的超微结构改变。
3.
Methods The model of sympathectomy mouse was established by injection of 6-OHDA intraperitoneally.
方法采用常规组织学和免疫组织化学技术,观察经腹腔注射交感神经损毁剂6-羟多巴胺后小鼠小肠上皮内淋巴细胞、杯状细胞、IgA+浆细胞、肥大细胞的数量分布变化。
5) 6-OH-dopamine
六羟多巴胺
6) Hydroxydopamine
羟基多巴胺
1.
Histopathological changes in the substantia nigra of Parkinson's disease rat model induced by 6-hydroxydopamine
应用6-羟基多巴胺建立帕金森病模型大鼠黑质神经组织病理学变化
补充资料：羟多巴胺
分子式：
CAS号：
性质：其盐酸盐为深棕色，熔点187℃。以多巴胺为原料制得。其药理作用与多巴胺相同。
CAS号：
性质：其盐酸盐为深棕色，熔点187℃。以多巴胺为原料制得。其药理作用与多巴胺相同。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条